Characteristics of the fecal microbiome and metabolome in older patients with heart failure and sarcopenia
Frontiers in Cellular and Infection Microbiology · 24.02.2023 · 13
DOI: 10.3389/fcimb.2023.1127041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 24.02.2023. Verfasst von Jieting Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Sarcopenia, Microbiota, Heart Failure. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Project of Research and Development Plan of Hunan Province, Natural Science Foundation of Hunan Province.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Increasing evidence supports that gut microbiota plays an important role in the development of cardiovascular diseases. The prevalence of sarcopenia is increasing in patients with heart failure. Muscle wasting is an independent predictor of death in heart failure patients.
Aims
In this study, we aimed to explore the characteristics of gut microbiota and metabolites in heart failure patients with or without sarcopenia.
Methods
Fecal samples of 33 heart failure patients without sarcopenia, 29 heart failure patients with sarcopenia, and 15 controls were collected. The intestinal microbiota was analyzed using 16S rRNA sequencing and the metabolites were detected using the gas chromatography-mass spectrometry method.
Results
There were significant differences in the overall microbial community structure and diversity between control and heart failure patients with or without sarcopenia. However, no clear clustering of samples was observed in heart failure with and without sarcopenia patients. Several bacterial, particularly Nocardiaceae , Pseudonocardiaceae, Alphaproteobacteria , and Slackia were significantly enriched in the heart failure patients without sarcopenia, while Synergistetes was more abundant in the heart failure patients with sarcopenia. Isobutyric acid, isovaleric acid, and valeric acid were lower in heart failure patients with sarcopenia than that without sarcopenia but lacked significance.
Conclusions
This study demonstrates that there are differences in the gut microbiota between control individuals and heart failure patients with or without sarcopenia. Modulating the gut microbiota may be a new target for the prevention and treatment of sarcopenia in heart failure patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatrics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Laboratory of Clinical Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Förderung
- National Natural Science Foundation of China
- Key Project of Research and Development Plan of Hunan Province
- Natural Science Foundation of Hunan Province
Zitieren
APA
Peng, J., Gong, H., Lyu, X., Liu, Y., Li, S., Tan, S., Dong, L., & Zhang, X. (2023). Characteristics of the fecal microbiome and metabolome in older patients with heart failure and sarcopenia. Frontiers in Cellular and Infection Microbiology, 13. https://doi.org/10.3389/fcimb.2023.1127041
Vancouver
Peng J, Gong H, Lyu X, Liu Y, Li S, Tan S, et al. Characteristics of the fecal microbiome and metabolome in older patients with heart failure and sarcopenia. Frontiers in Cellular and Infection Microbiology. 2023;13. doi:10.3389/fcimb.2023.1127041
BibTeX
@article{Peng2023,
author = {Peng, Jieting and Gong, Hui and Lyu, Xing and Liu, Yang and Li, Shizhen and Tan, Shengyu and Dong, Lini and Zhang, Xiangyu},
title = {Characteristics of the fecal microbiome and metabolome in older patients with heart failure and sarcopenia},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
volume = {13},
doi = {10.3389/fcimb.2023.1127041}
}
EUVIMED